口服降血糖藥市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、最終用戶、地區和競爭對手分類，2021-2031年

全球口服糖尿病藥物市場預計將從 2025 年的 186.7 億美元大幅成長至 2031 年的 280.7 億美元，複合年成長率高達 7.03%。

這些口服藥物透過促進胰島素分泌、提高胰島素敏感性或抑制葡萄糖吸收，在控制第二型糖尿病患者的血糖值方面發揮著至關重要的作用。該市場的成長主要受全球第2型糖尿病盛行率不斷上升的驅動。根據國際糖尿病聯盟（IDF）預測，到2025年，全球約有5.89億20至79歲的成年人患有第2型糖尿病，佔成年人口的11.1%。這種廣泛的盛行率與人口老化和久坐的生活方式密切相關，導致對有效口服療法的需求持續成長，預計到2025年，與糖尿病相關的醫療保健支出將達到1兆美元。此外，新型口服藥物的分類和製劑的進步，例如GLP-1受體激動劑口服促效劑的成功上市，也推動了市場的發展。這些藥物正在取代侵入性注射療法，提高患者依從性，並擴大市場覆蓋範圍。諾和諾德公司 2025 年第三季財報顯示，其「Libelsus」品牌銷售額為 54.42 億丹麥克朗，這徵兆了這種轉變。

市場促進因素

全球第2型糖尿病盛行率的持續上升是全球口服降血糖藥市場的主要驅動力。這種日益加重的疾病負擔與肥胖率上升和久坐不動的生活方式密切相關，從而導致對有效口服降血糖療法的持續需求。隨著需要終身管理的患者群體不斷擴大，人們越來越依賴易於獲得的藥物來緩解長期健康併發症。根據國際糖尿病聯盟（IDF）於2025年12月發布的第11版《糖尿病地圖集》，目前全球11.1%的成年人患有糖尿病。這種廣泛的盛行率正在推動醫療保健領域的巨大經濟活動。 IDF估計，到2025年，全球整體用於糖尿病的醫療保健支出將達到約1兆美元，凸顯了用於治療管理和疾病控制的巨額資金。新型口服藥物類別和製劑的進步是另一個關鍵促進因素，它們透過以便捷的口服給藥取代侵入性給藥方式，從根本上改變了患者照護方式。該領域的創新使得將GLP-1受體促效劑等複雜分子成功製成片劑成為可能，從而克服了注射療法的傳統障礙。這項技術變革顯著提高了患者的依從性，並將先進治療方法的市場拓展至傳統注射之外。這些製劑的快速上市體現在近期的企業績效數據。根據諾和諾德於2025年11月發布的《2025年第三季財務業績報告》，其旗艦口服GLP-1療法Rybelsus僅在第三季度的銷售額就達到了54.42億丹麥克朗，這表明市場對高效且非侵入性的治療方法有著強勁的需求。

市場挑戰

中低收入國家先進口服糖尿病藥物的供應有限，對製藥公司的收入成長構成重大障礙。儘管這些地區的糖尿病患者群體正在迅速成長，但有限的醫療預算和不完善的報銷機制往往阻礙了高價藥物的引入。因此，為了控制治療成本，醫療服務提供者和患者通常優先選擇性價比更高的學名藥。這種經濟壓力嚴重限制了高價值產品的市場滲透率，並限制了新治療方法研發者的投資回報。這種差異造成了區域疾病負擔與實際市場價值之間的明顯差距，阻礙了企業在糖尿病高銷售量地區實現創新成果的商業化。根據國際糖尿病聯盟（IDF）預測，到2025年，儘管中低收入國家擁有全球絕大多數的糖尿病患者，但其糖尿病相關醫療保健支出僅佔全球的9.3%。這種購買力的不足迫使市場更依賴銷售量而非銷售額，導致主要產業參與者的利潤率下降，並減緩了全球糖尿病產業的財務擴張。

市場趨勢

隨著臨床指引日益重視SGLT2抑制劑在血糖控制和心臟和腎臟功能方面的益處，其應用範圍的不斷擴大正在重塑市場格局。醫生開始使用這類藥物來緩解心臟衰竭和慢性腎臟病，這類藥物正逐漸成為心臟代謝管理的重要支柱。這一轉變顯著提升了現有公司的收入，這些公司已獲得了針對這些合併症的擴展適應症，從而有效地在傳統糖尿病治療之外開闢了一個新的成長領域。Astra Zeneca於2024年11月發布的2024年第三季財報顯示，受心臟衰竭和腎臟病治療需求成長的推動，其藥物Farxiga的銷售額在第三季成長了27%，凸顯了這種廣泛治療用途的商業性影響力。同時，隨著Dipeptidyl Peptidase-4 (DPP-4) 抑制劑專利到期，學名藥市場進入速度加快，也正在改變該產業的格局。隨著主要專利保護到期，價格更低廉的替代藥物湧入市場，迅速蠶食老牌藥物的市場佔有率，同時患者的用藥途徑也隨之擴大。這種壓力迫使先行藥廠調整策略，因為價值正從成熟產品轉向更新、專利保護更完善的藥物類別。根據默克公司2024年10月發布的2024年第三季財報，其品牌藥捷諾維（Januvia）的銷售額下降了49%，至2.78億美元。這主要反映了美國和國際市場上學名藥激烈競爭的影響。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：口服降血糖藥全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物特定分類（雙胍類、α-葡萄Glucosidase抑制劑、多巴胺D2受體促效劑、鈉-葡萄糖共同輸送體2 (SGLT-2) 抑制劑、Dipeptidyl Peptidase4 (DPP-4) 抑制劑、磺醯尿素類、Meglitinides）
  • 依最終使用者（醫院、居家醫療、專科醫療中心等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美口服降血糖藥市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲口服降血糖藥市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區口服降血糖藥市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲口服降血糖藥市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲口服降血糖藥市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球口服降血糖藥市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• KONINKLIJKE PHILIPS NV
• Sanofi SA
• Eli Lilly and Company
• AstraZeneca Plc.
• Astellas Pharma Inc.
• Johnson & Johnson
• CH Boehringer Sohn AG & Co. KG
• Merck And Co. Inc.
• Bristol Myers Squibb Company
• Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Oral Anti-Diabetic Drugs Market is projected to expand significantly from USD 18.67 Billion in 2025 to USD 28.07 Billion by 2031, demonstrating a robust 7.03% CAGR. These orally administered pharmaceutical agents are crucial for managing blood glucose levels in Type 2 diabetes patients by boosting insulin secretion, enhancing insulin sensitivity, or curbing glucose absorption. This market growth is primarily fueled by the increasing global prevalence of Type 2 diabetes, which affected approximately 589 million adults aged 20 to 79 worldwide in 2025 according to the International Diabetes Federation, representing 11.1% of the adult population. This widespread incidence, linked to aging populations and sedentary lifestyles, creates continuous demand for effective oral therapies and contributes to a global expenditure on diabetes-related healthcare estimated at USD 1 trillion in 2025. Further propelling the market are advancements in novel oral drug classes and formulations, such as the successful oral formulation of GLP-1 receptor agonists, which replace invasive injectable treatments, thereby improving patient adherence and expanding market reach. Evidence of this shift is seen in Novo Nordisk's Q3 2025 financial report, which recorded Rybelsus sales of DKK 5,442 million.

Market Driver

The escalating global prevalence of Type 2 diabetes serves as the primary driver propelling the Global Oral Anti-Diabetic Drugs Market. This expanding disease burden is inextricably linked to rising obesity rates and sedentary lifestyles, creating a continuous demand for effective oral glucose-lowering therapies. As the patient demographic requiring lifelong management widens, the reliance on accessible pharmaceutical interventions intensifies to mitigate long-term health complications. According to the International Diabetes Federation, December 2025, in the 'IDF Diabetes Atlas 11th Edition', it was revealed that 11.1% of the adult population worldwide is currently living with diabetes. This widespread incidence translates into substantial economic activity within the healthcare sector. According to the International Diabetes Federation, in 2025, global expenditure on diabetes-related healthcare was estimated to be approximately USD 1 trillion, underscoring the massive financial resources directed toward therapeutic management and disease control.Advancements in novel oral drug classes and formulations represent the second critical driver, fundamentally reshaping patient care by replacing invasive delivery methods with convenient oral options. Innovation in this sector is enabling the successful formulation of complex molecules, such as GLP-1 receptor agonists, into tablets, thereby overcoming the historical barriers associated with injectable treatments. This technological shift significantly improves patient adherence and expands the addressable market for advanced therapies beyond traditional injectables. The rapid commercial adoption of these formulations is reflected in recent corporate performance data. According to Novo Nordisk, November 2025, in the 'Q3 2025 Financial Report', sales of Rybelsus, a prominent oral GLP-1 therapy, reached DKK 5,442 million in the third quarter alone, demonstrating the strong market preference for effective, non-invasive treatment modalities.

Market Challenge

The limited affordability of advanced oral anti-diabetic medications in low- and middle-income countries presents a substantial barrier to revenue growth for pharmaceutical manufacturers. Although these regions represent a rapidly expanding patient base, restricted healthcare budgets and insufficient reimbursement frameworks often prevent the wide adoption of premium drug classes. Consequently, healthcare providers and patients frequently prioritize cost-effective generic alternatives over newer branded therapies to manage treatment costs. This economic pressure significantly limits the market penetration of high-value products and constrains the commercial return on investment for developers of novel treatments.This disparity creates a clear disconnect between regional disease burden and actual market value, hindering the ability of companies to monetize innovation in high-volume territories. According to the International Diabetes Federation, in 2025, low- and middle-income countries accounted for only 9.3% of global diabetes-related health expenditure despite hosting the majority of the global diabetic population. This lack of purchasing power forces the market to rely heavily on volume rather than value, thereby reducing profit margins for major industry players and dampening the overall financial expansion of the global sector.

Market Trends

The expanding utilization of SGLT2 inhibitors is reshaping the market as clinical guidelines increasingly prioritize these agents for cardio-renal benefits rather than solely for glycemic control. Physicians are prescribing these therapies to mitigate heart failure and chronic kidney disease, transitioning the drug class to a fundamental pillar of cardio-metabolic management. This shift significantly amplifies revenue for incumbents securing label expansions for these comorbidities, effectively creating a new growth vertical beyond traditional diabetes care. According to AstraZeneca, November 2024, in the 'Q3 2024 Results', expanding demand for heart failure and kidney disease treatments drove Farxiga revenue to grow by 27% in the third quarter, confirming the commercial impact of this broader therapeutic application.Concurrently, the acceleration of generic market entry following patent expiries for blockbuster dipeptidyl peptidase-4 (DPP-4) inhibitors is structurally altering the sector. The expiration of key protections has triggered an influx of cost-effective alternatives, rapidly eroding the share of established brands while broadening patient access. This pressure forces originators to pivot strategies as value shifts away from mature assets toward newer, protected drug classes. According to Merck & Co., October 2024, in the 'Third-Quarter 2024 Financial Results', sales of the branded therapy Januvia declined by 49% to USD 278 million, primarily reflecting the intense impact of generic competition in the United States and international markets.

Key Market Players

• KONINKLIJKE PHILIPS N.V.
• Sanofi S.A.
• Eli Lilly and Company
• AstraZeneca Plc.
• Astellas Pharma Inc.
• Johnson & Johnson
• C.H. Boehringer Sohn AG & Co. KG
• Merck And Co. Inc.
• Bristol Myers Squibb Company
• Novartis AG

Report Scope

In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Anti-Diabetic Drugs Market, By Drugs

• Biguanides
• Alpha-glucosidase inhibitors
• Dopamine -D2 Receptor Agonist
• Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
• Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
• Sulfonylureas
• Meglitinides

Oral Anti-Diabetic Drugs Market, By End Users

• Hospitals
• Homecare
• Speciality Centers
• Others

Oral Anti-Diabetic Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market.

Available Customizations:

Global Oral Anti-Diabetic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Anti-Diabetic Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides)
  • 5.2.2. By End Users (Hospitals, Homecare, Speciality Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Oral Anti-Diabetic Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By End Users
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By End Users
  • 6.3.2. Canada Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By End Users
  • 6.3.3. Mexico Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By End Users

7. Europe Oral Anti-Diabetic Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By End Users
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By End Users
  • 7.3.2. France Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By End Users
  • 7.3.3. United Kingdom Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By End Users
  • 7.3.4. Italy Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By End Users
  • 7.3.5. Spain Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By End Users

8. Asia Pacific Oral Anti-Diabetic Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By End Users
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By End Users
  • 8.3.2. India Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By End Users
  • 8.3.3. Japan Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By End Users
  • 8.3.4. South Korea Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By End Users
  • 8.3.5. Australia Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By End Users

9. Middle East & Africa Oral Anti-Diabetic Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By End Users
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By End Users
  • 9.3.2. UAE Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By End Users
  • 9.3.3. South Africa Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By End Users

10. South America Oral Anti-Diabetic Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By End Users
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By End Users
  • 10.3.2. Colombia Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By End Users
  • 10.3.3. Argentina Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oral Anti-Diabetic Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. KONINKLIJKE PHILIPS N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Eli Lilly and Company
• 15.4. AstraZeneca Plc.
• 15.5. Astellas Pharma Inc.
• 15.6. Johnson & Johnson
• 15.7. C.H. Boehringer Sohn AG & Co. KG
• 15.8. Merck And Co. Inc.
• 15.9. Bristol Myers Squibb Company
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer